India to France: Artemether Export Trade Route

To import Artemether formulations into France, the following approvals and registrations are necessary:

• Marketing Authorization: A valid marketing authorization is mandatory for all medicinal products entering the European Union (EU) market. Applications must be submitted in the Common Technical Document (CTD) or electronic CTD (eCTD) format.

• Manufacturing and Import Authorization: Entities involved in the manufacture or import of medicinal products must obtain authorization from the relevant national competent authority. This authorization ensures compliance with Good Manufacturing Practice (GMP) standards.

• GMP Compliance: Manufacturers, including those outside the EU, must comply with EU GMP standards. This compliance is verified through inspections conducted by EU authorities or recognized under Mutual Recognition Agreements (MRAs).

• GMP Inspection Requirements: Indian manufacturing facilities producing Artemether formulations intended for the French market are subject to GMP inspections by EU authorities. These inspections assess adherence to EU GMP standards and are a prerequisite for obtaining manufacturing authorization.

• Product Registration Fees: Fees associated with marketing authorization applications vary depending on the specific product and application type.

Indian exporters of Artemether formulations must meet the following quality and GMP standards to supply the French market:

• GMP Certification: Manufacturers must hold GMP certification that aligns with EU standards. This certification is obtained through successful inspections by EU authorities or under MRAs.

• Approved Facilities: Only manufacturing facilities that have been inspected and approved by EU authorities are authorized to export to the EU.

• Recent Inspections and Regulatory Actions: EU authorities regularly inspect Indian pharmaceutical facilities to ensure compliance with GMP standards. Non-compliance can result in regulatory actions, including the issuance of non-compliance statements.

Several regulatory developments between 2024 and 2026 have impacted Indian pharmaceutical exports to France:

• Revision of GMP Guidelines: In February 2026, the EMA initiated public consultations on revising Annex 6 (Manufacture of Medicinal Gases) and Annex 15 (Qualification and Validation) of the GMP guidelines. These revisions aim to reflect current industry practices and technological advancements.

• International Collaboration: The EMA continues to participate in international programs to rationalize GMP inspections of active substance manufacturers. This collaboration aims to enhance cooperation and mutual confidence among regulatory authorities, facilitating the monitoring of manufacturing sites and reducing unnecessary duplication of inspections.

Staying informed about these regulatory changes is crucial for Indian exporters to ensure continued compliance and market access to France.

In 2025, France reported approximately 2,500 imported malaria cases, primarily due to travel and immigration from endemic regions. This has sustained a consistent demand for Artemether-based treatments. The French healthcare system, characterized by universal coverage and substantial public health funding, ensures the availability and accessibility of antimalarial medications. While France possesses a robust pharmaceutical manufacturing sector, the specific production levels of Artemether formulations domestically are not publicly disclosed. Consequently, imports, particularly from India, play a crucial role in meeting the national demand for these medications.

Pharmaceutical products under HS code 30046000, including Artemether formulations, are subject to a 0% import duty in France. Additionally, these products are exempt from Value Added Tax (VAT), aligning with France's policy to facilitate access to essential medicines. There are no Free Trade Agreements (FTAs) between India and France that specifically alter this tariff structure for pharmaceutical imports. Furthermore, no anti-dumping duties are imposed on Artemether formulations imported from India, ensuring a favorable trade environment for these products.

India is a significant supplier of Artemether formulations to France, with exports valued at $14.2 million USD, accounting for 1.6% of India's total Artemether formulation exports. While specific data on other major supplying countries is not detailed, India's competitive pricing and established pharmaceutical manufacturing capabilities position it as a key player in the French market. Comparatively, India's pricing for Artemether formulations is generally more competitive than that of European manufacturers, including those within France, due to lower production costs. This cost advantage, coupled with the absence of import duties and VAT, enhances the attractiveness of Indian Artemether formulations in the French market.

India is a leading global producer of generic pharmaceuticals, accounting for approximately 20% of the global supply by volume. This extensive manufacturing capability extends to antimalarial medications, including formulations containing artemether. The country's pharmaceutical industry comprises over 3,000 companies and more than 10,500 manufacturing facilities, many of which are dedicated to producing finished dosage forms such as tablets, capsules, syrups, and injections. India's cost-effective production is attributed to economies of scale, a skilled workforce, and a well-established supply chain. As of November 2023, Indian pharmaceutical companies have filed 5,637 Type II Active Drug Master Files (DMFs) with the US FDA, indicating a strong presence in the global market. Additionally, India has the highest number of US FDA-approved manufacturing sites outside the USA, with 748 sites registered as of April 2024. This includes both finished dosage form (FDF) facilities and active pharmaceutical ingredient (API) facilities, underscoring India's commitment to maintaining high-quality manufacturing standards.

When comparing artemether formulations from India, China, and the European Union (EU), several factors come into play:

• Cost: Indian manufacturers offer artemether formulations at competitive prices due to lower production costs and economies of scale. Chinese manufacturers also provide cost-effective options; however, India's established supply chain and regulatory compliance often result in better value. EU-produced artemether formulations are typically more expensive, reflecting higher labor costs and stringent regulatory requirements.

• Quality Perception: India's pharmaceutical industry is recognized for adhering to international quality standards, with numerous facilities holding WHO-GMP and US FDA approvals. China has made significant strides in improving quality but still faces challenges in meeting certain international standards. EU manufacturers are generally perceived as producing high-quality products, albeit at a higher cost.

• Regulatory Acceptance in France: Indian artemether formulations have gained acceptance in France, as evidenced by the trade data indicating substantial imports from India. Chinese products face more scrutiny due to past quality concerns, while EU products are readily accepted but come with higher costs.

• Supply Reliability: India has a strong track record of reliable supply, supported by a vast manufacturing base and established logistics networks. China's supply reliability has improved but can be affected by regulatory changes and geopolitical factors. EU manufacturers offer reliable supply but may have longer lead times and higher costs.

India's pharmaceutical industry demonstrates robust manufacturing capacity for artemether formulations, supported by a vast network of over 10,500 manufacturing facilities. These facilities are equipped with advanced packaging and cold chain capabilities, ensuring the stability and efficacy of temperature-sensitive products. The regulatory compliance track record of Indian manufacturers is strong, with numerous facilities holding WHO-GMP and US FDA approvals. While specific data on recent supply disruptions are not available, the industry's scale and infrastructure suggest a resilient supply chain. Top Indian manufacturers continue to invest in capacity expansion to meet growing global demand for artemether formulations.

For French buyers sourcing artemether formulations from India, the following strategies are recommended:

• Dual-Sourcing Strategy: Engage with multiple Indian manufacturers to mitigate risks associated with supply disruptions and ensure a consistent supply of artemether formulations.

• Minimum Order Quantities (MOQs): Be aware that Indian manufacturers may have MOQs to optimize production efficiency. Discuss and negotiate these quantities to align with your procurement needs.

• Payment Terms: Standard payment terms in India-France pharmaceutical trade often include letters of credit (LC) or advance payments. Establish clear payment agreements to maintain smooth transactions.

• Supplier Qualification Process: Conduct thorough due diligence, including audits of manufacturing facilities, verification of regulatory approvals (such as WHO-GMP and US FDA certifications), and assessment of quality control systems to ensure compliance with international standards.

• Regulatory Compliance: Ensure that the selected suppliers comply with both Indian and French regulatory requirements, facilitating seamless importation and distribution within France.

1. Certificate of Analysis (CoA): Provides detailed results of laboratory testing for each batch, confirming the product meets specified quality standards.

2. Certificate of Origin (CoO): Certifies the country where the product was manufactured, essential for customs and regulatory purposes.

3. GMP Certificate: Demonstrates that the manufacturing facility complies with Good Manufacturing Practice regulations, ensuring product quality and safety.

4. Stability Data: Includes studies conducted under International Council for Harmonisation (ICH) guidelines to demonstrate the product's shelf life and storage conditions across different climatic zones.

5. Batch Records: Detailed documentation of the manufacturing process for each batch, ensuring traceability and consistency in production.

6. Drug Master File (DMF): Comprehensive document submitted to regulatory agencies detailing the manufacturing, processing, packaging, and storage of the drug product.

7. Free Sale Certificate: Issued by the Central Drugs Standard Control Organisation (CDSCO), indicating that the product is approved for sale in the country of origin and is freely sold in the market.

8. Insurance Certificates: Proof of liability insurance coverage, ensuring protection against potential claims related to product quality or safety issues.

By adhering to this structured approach, French companies can effectively qualify Indian suppliers of Artemether formulations, ensuring compliance with regulatory standards and safeguarding product quality.